RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Fudan University Shanghai Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07194005, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Histologically and/or cytologically confirmed unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma;

    Inclusion criterion 3

  3. Prior systemic antitumor therapy (including Chinese herbal medicine with antitumor indications) completed less than 4 weeks before the first dose of study treatment, or with prior treatment-related adverse events not recovered to ≤ CTCAE grade 1 (except for alopecia or pigmentation).

    Exclusion criterion 6

    Use of systemic immunosuppressive therapy within 2 weeks prior to enrollment, or anticipated need for such therapy during the study, with the following exceptions:

    Exclusion criterion 9

  4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;

    Inclusion criterion 9

  5. Hemoglobin ≥ 90 g/L;

    Inclusion criterion 11

    Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L;

    Inclusion criterion 12

    Platelet count ≥ 80 × 10⁹/L;

    Inclusion criterion 14

    Total bilirubin ≤ 2 × upper limit of normal (ULN);

    Inclusion criterion 16

    Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 2.5 × ULN in the absence of liver metastases; or ≤ 5 × ULN if liver metastases are present;

    Inclusion criterion 17

    Serum creatinine ≤ 1.5 × ULN; or creatinine clearance (CrCl) ≥ 50 mL/min as calculated by the Cockcroft-Gault formula;

    Inclusion criterion 18

    International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN;

    Inclusion criterion 19

    Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.

    Inclusion criterion 20

  6. At least one measurable lesion per RECIST 1.1;

    Inclusion criterion 7

  7. Malignancies treated with curative intent and with no evidence of disease for 5 years;

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07194005, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily enrolled and provided written informed consent;
  • Aged 18-70 years (inclusive), male or female;
  • Histologically and/or cytologically confirmed unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma;
  • No prior systemic anticancer therapy;
  • HER2 immunohistochemistry (IHC) result of 2+ or 1+, based on either previous test results (confirmed by the investigator) or central laboratory assessment;
  • Presence of a single initial unresectable factor;
  • At least one measurable lesion per RECIST 1.1;
  • Life expectancy ≥ 6 months;
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;
  • Adequate organ function, defined as follows:

Hematological (within 14 days prior to screening, without transfusion or granulocyte colony-stimulating factor [G-CSF] support):

  • Hemoglobin ≥ 90 g/L;
  • Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L;
  • White blood cell count ≥ 3.0 × 10⁹/L;
  • Platelet count ≥ 80 × 10⁹/L;

Biochemical (within 14 days prior to screening, without albumin infusion):

  • Albumin ≥ 28 g/L;
  • Total bilirubin ≤ 2 × upper limit of normal (ULN);
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 2.5 × ULN in the absence of liver metastases; or ≤ 5 × ULN if liver metastases are present;
  • Serum creatinine ≤ 1.5 × ULN; or creatinine clearance (CrCl) ≥ 50 mL/min as calculated by the Cockcroft-Gault formula;

Coagulation:

  • International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN;
  • Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.

Exclusion Criteria:

  • History of malignancies other than gastric cancer, with the following exceptions:
  • Malignancies treated with curative intent and with no evidence of disease for 5 years;
  • Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, superficial bladder cancer, cervical carcinoma in situ, or other in situ carcinomas.
  • Conditions affecting the absorption, distribution, metabolism, or excretion of the investigational drug(s) (e.g., severe vomiting, chronic diarrhea, intestinal obstruction, malabsorption, etc.).
  • Previous allogeneic stem cell or solid organ transplantation.
  • Prior systemic antitumor therapy (including Chinese herbal medicine with antitumor indications) completed less than 4 weeks before the first dose of study treatment, or with prior treatment-related adverse events not recovered to ≤ CTCAE grade 1 (except for alopecia or pigmentation).
  • History or presence of congenital or acquired immunodeficiency disorders.
  • Active or previously documented autoimmune or inflammatory disorders (including but not limited to autoimmune hepatitis, interstitial pneumonia, inflammatory bowel disease, systemic lupus erythematosus, vasculitis, uveitis, hypophysitis, hyperthyroidism, hypothyroidism, asthma requiring bronchodilators, etc.). Patients with vitiligo, childhood asthma that has fully resolved without intervention in adulthood, or other conditions deemed eligible by the investigator may be included.
  • Use of systemic immunosuppressive therapy within 2 weeks prior to enrollment, or anticipated need for such therapy during the study, with the following exceptions:
  • Intranasal, inhaled, topical, or local corticosteroid injections (e.g., intra-articular);
  • Systemic corticosteroids at a dose ≤ 10 mg/day prednisone or equivalent;
  • Prophylactic corticosteroids for hypersensitivity reactions.
  • Known or suspected history of hypersensitivity to disitamab vedotin, anti-PD-1 agents, chimeric or humanized antibodies or fusion proteins, or any excipient of the investigational drug(s).
  • History of thrombotic or thromboembolic events within the past 6 months, such as stroke and/or transient ischemic attack, deep vein thrombosis, pulmonary embolism, etc.
  • Patients assessed by the physician to be at significant risk of bleeding, including but not limited to:
  • Major bleeding (>30 mL within 3 months) or hemoptysis (>5 mL within 4 weeks); endoscopic evaluation may be performed to confirm eligibility;
  • Active bleeding or coagulation disorders;
  • Bleeding tendency or current use of thrombolytic, anticoagulant, or antiplatelet therapy.

Quoted from ClinicalTrials.gov, NCT07194005, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07194005, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07194005